Patient preferences for atopic dermatitis treatments: a discrete choice experiment

Abstract

Background

Patients with moderate-to-severe atopic dermatitis (AD) experience skin lesions and intense itch that substantially affect quality of life. Patients have choices among systemic AD treatments that offer varied benefit–risk profiles.

Objective

Measure patients’ willingness to trade off the risks and benefits of systemic treatments among individuals with a physician-confirmed diagnosis of moderate-to-severe AD.

Methods

Patients participated in a discrete choice experiment online survey with a series of choices between hypothetical AD treatments defined by six attributes reflecting benefits and risks of treatments (itch reduction, time until noticeable itch reduction, chance of clear or almost clear skin, risk of serious infection, risk of developing acne, and need for prescription topical steroids). Data were analyzed with a random parameters logit model to quantify preferences and the relative importance of attributes for treatment alternatives.

Results

Respondents (n = 200) placed the highest relative importance on itch reduction, speed of itch reduction, and skin clearance, and were generally willing to accept clinically relevant levels of risk of serious infection and acne in exchange for treatment benefits.

Conclusions

Patients with moderate-to-severe AD were willing to trade clinically relevant treatment risks for greater or more rapid itch reduction and skin clearance offered by systemic therapies.

Keywords:

• Atopic dermatitis
• conditional relative importance
• discrete choice experiment
• patient preference

Acknowledgements

AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. AbbVie and authors thank all respondents who participated in this study. Medical writing support, funded by AbbVie, was provided by Callie A. S. Corsa, PhD, and Lamara D. Shrode, PhD, ISMPP CMPP™, of JB Ashtin, who developed the first draft based on an author-approved outline and assisted in implementing author revisions. JB Ashtin adheres to Good Publication Practice (GPP3) guidelines and International Committee of Medical Journal Editors (ICMJE) recommendations.

Disclosure statement

Dr. Kwatra is an advisory board member/consultant for AbbVie, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals. He has served as an investigator for Galderma, Pfizer, and Sanofi. Dr. Lio has received research grants/funding from AbbVie, AOBiome, the National Eczema Association, and Regeneron/Sanofi Genzyme. He participates in speaker’s bureaus for Eli Lilly, Galderma, Incyte, L’Oreal, LEO Pharma, Pfizer, and Regeneron/Sanofi Genzyme. He reports payments for serving as a consultant or participating on advisory boards for AbbVie, Almirall, Amyris, AOBiome, Arbonne, Aslan, Bodewell, Bristol Myers Squibb, Burt’s Bees, Concerto Biosciences (stock options), Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, Kiniksa, LEO Pharma, L’Oreal, Menlo Therapeutics, Merck, Micreos (stock options), My-Or Diagnostics, Pierre-Fabre, Pfizer, Realm Therapeutics, Regeneron/Sanofi Genzyme, Sibel Health, Theraplex, UCB, Unilever, and Verrica. In addition, Dr. Lio has a patent pending for a Theraplex product and receives royalty payments for the patent. He is also a board member and scientific advisory committee member of the National Eczema Association. Dr. Weidinger is a speaker, advisory board member, and/or investigator for AbbVie, Almirall, Eli Lilly, Galderma, Kymab, LEO Pharma, Pfizer, Regeneron, and Sanofi. He has received research grants from La Roche Posay, LEO Pharma, Pfizer, and Sanofi Germany. Drs. Calimlim, Ladizinski, and Vigna are full-time employees of AbbVie Inc. and may own AbbVie stock and/or stock options. Dr. Botha is a former employee of RTI Health Solutions, which received funding from AbbVie Inc. to conduct the study. He was an employee of RTI Health Solutions at the time the study was conducted. Dr. Mansfield is a current employee of RTI Health Solutions, which received funding from AbbVie Inc. to conduct the study.

Data availability statement

AbbVie is committed to responsible data sharing regarding the studies we sponsor. This includes access to anonymized individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing agreement. Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvieclinicaltrials.com/hcp/data-sharing/.html.

Additional information

Funding

This work was funded by AbbVie Inc.